Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A07139 | Pages: 257 | Charts: 40 | Tables: 123 |
The global veterinary oncology market size was valued at $297.30 million in 2020, and is estimated to reach $819.84 million by 2030, growing at a CAGR of 10.8% from 2021 to 2030.
[COVIDIMPACTSTATEMENT]
Veterinary oncology is defined as the treatment of pets suffering from cancer to enhance the quality of life. Cancer is one of the major cause of death in pet animals. Dogs and cats are more prone to develop skin cancer and bone cancer. Skin tumor is most common and frequently diagnosed cancer in domestic animals due to constant exposure of animal skin to sun rays. The HHHHHMM scale is used by veterinarians to identify the quality of life with pet owners before decisions are made for treatment of disease such as cancer.
Get more information on this report : Request Sample Pages
The growth of the global veterinary oncology market is majorly driven by increase in the prevalence of cancer, such as lymphoma, skin cancer, mast cell cancer, & bone cancer; rise in demand for veterinary oncology therapy; increase in funding from private & government organizations for animal care centers; and rise in R&D activities for oncology treatment in pets. According to the Flint Animal Cancer Center, in 2020, it was reported that approximately 85% of bone tumor are diagnosed in canine animal. Furthermore, surge in pet adoption is anticipated to fuel the growth of the infection disease diagnostic market. For instance, in January 2021, American Veterinary Medical Association, it was observed that the number of new pets per practice increase from 25% per week in March 2020 to 39% in July 2020. In addition, rise in focus on pet health fuels the market growth, owing to the fact that dogs and cats are more susceptible to cancer. According to the Journal of American Animal Hospital Association, it was reported that dogs are more prone to cancer.
In addition, increase in the number of veterinary clinical studies for evaluating the safety and efficiency of a wide range of oncology drugs is anticipated to contribute toward the growth of the veterinary oncology market. According to the National Cancer Institute, in 2020, the Pre-Medical Cancer Immunotherapy Network of Canine Trails and comparative oncology programs facilitated the trials of novel therapies for different type of cancer in pets such as dogs.
Furthermore, rise in awareness among individuals for management and treatment of oncology in pets and increase in the number of veterinary clinical centers to develop advanced treatment therapies are expected to provide remunerative opportunities for the expansion of the global veterinary oncology market during the forecast period. Moreover, the presence of key manufacturing company in veterinary oncology treatment and rise in expenditure on animal healthcare propel the growth of the veterinary oncology market.
Thus, presence of various veterinary foundations and initiatives taken by government for regarding pet illness propel the growth of the market. However, high cost associated with veterinary oncology therapy and side effects of oncology drugs such as hair loss, decrease appetite, and vomiting are expected to restrict the market growth during the forecast period.
The global veterinary oncology market is segmented into therapy, animal type, cancer, and region. By therapy, the market is categorized into surgery, radiology, chemotherapy, and others.
On the basis of animal type, it is divided into canine and feline. Depending on cancer, it is categorized into lymphoma, mast cell cancer, mammary and squamous cell cancer, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on therapy, the chemotherapy segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to advancement in R&D activities in the animal healthcare sector, increase in number of chemotherapy in animal for treatment of cancer, and surge in adoption of chemotherapies procedures in pets. However, the radiology segment is expected to witness considerable growth during the forecast period, owing to surge in number of research study for animal treatment and surge in adoption of target specific therapy for pets.
[THERAPYGRAPH]
Get more information on this report : Request Sample Pages
By animal type, the canine segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in incidence of cancer in canine animals, rise in R&D activities for oncology treatment in animals, and increase in number of clinical trials on canine for oncology treatment. However, the feline segment is expected to witness considerable growth during the forecast period, due to increase in prevalence of cancer in feline, rise in the number of cats, and development of clinical study in feline to identify the safety & efficacy of oncology treatment.
[ANIMALTYPEGRAPH]
Get more information on this report : Request Sample Pages
On the basis of cancer, the lymphoma segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in demand for chemotherapy, rise in prevalence of mast cell cancer in dogs, and advancement in R&D activities for lymphoma cancer treatment. However, the mast cell cancer segment is expected to witness considerable growth during the forecast period, owing to increase in number of veterinary cancer study, surge in awareness about treatment of skin cancer, and advancements in R&D for oncology treatment in animals.
[CANCERGRAPH]
Get more information on this report : Request Sample Pages
North America garnered the major share in the veterinary oncology market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in the prevalence of cancer in pet animals, presence of key players for manufacturing & developing drugs for animals, increase in number of dogs & cats, and initiatives taken by government for pet oncology treatment in the region. However, Asia-Pacific is expected to register the highest CAGR of 11.9% from 2021 to 2030, owing to increase in prevalence of cancer in dogs, rise in demand for pet adoption, and presence of various veterinary foundations.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
The key players operating in the global veterinary oncology market include Accuray Incorporated, Boehringer Ingelheim International GmbH, Elanco, Karyopharm Therapeutics, Inc., Morphogenesis, Inc., Nippon Zenyaku Kogyo Co., PetCure Oncology, Regeneus Ltd., Varian Medical System, Inc., and Zoetis.
Key Benefits For Stakeholders
Key Market Segments
By Therapy
By Animal Type
By Cancer
By Region
KEY MARKET PLAYERS
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in prevalence of cancer in animal
3.5.1.2.Growth in veterinary healthcare expenditure and development in pet insurance policy
3.5.1.3.Increase in R&D activities for veterinary cancer therapy
3.5.2.Restraint
3.5.2.1.High cost of therapies for the treatment of veterinary oncology
3.5.3.Opportunity
3.5.3.1.Increase in number of veterinary clinical trial studies
3.5.4.Impact analysis
3.6.Impact analysis of COVID-19 on the veterinary oncology market
CHAPTER 4:VETERINARY ONCOLOGY MARKET, BY THERAPY
4.1.Overview
4.1.1.Market size and forecast
4.2.Surgery
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Radiology
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.5.Chemotherapy
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Others
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
CHAPTER 5:VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Canine
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by region
5.2.2.1.Canine by therapy
5.2.3.Market analysis, by country
5.3.Feline
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by region
5.3.2.1.Feline by therapy
5.3.3.Market analysis, by country
CHAPTER 6:VETERINARY ONCOLOGY MARKET, BY CANCER
6.1.Overview
6.1.1.Market size and forecast
6.2.Lymphoma
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country
6.3.Mast Cell Cancer
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country
6.4.Mammary and Squamous Cell Cancer
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country
6.5.Others
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market analysis, by country
CHAPTER 7:VETERINARY ONCOLOGY MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America veterinary oncology market, by therapy
7.2.3.North America veterinary oncology market, by animal type
7.2.4.North America veterinary oncology market, by cancer
7.2.5.Market size and forecast, by country
7.2.5.1.U.S.
7.2.5.1.1.U.S. veterinary oncology market, by therapy
7.2.5.1.2.U.S. veterinary oncology market, by animal type
7.2.5.1.3.U.S. veterinary oncology market, by cancer
7.2.5.2.Canada
7.2.5.2.1.Canada veterinary oncology market, by therapy
7.2.5.2.2.Canada veterinary oncology market, by animal type
7.2.5.2.3.Canada veterinary oncology market, by cancer
7.2.5.3.Mexico
7.2.5.3.1.Mexico veterinary oncology market, by therapy
7.2.5.3.2.Mexico veterinary oncology market, by animal type
7.2.5.3.3.Mexico veterinary oncology market, by cancer
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe veterinary oncology market, by therapy
7.3.3.Europe veterinary oncology market, by animal type
7.3.4.Europe veterinary oncology market, by cancer
7.3.5.Market size and forecast, by country
7.3.5.1.Germany
7.3.5.1.1.Germany veterinary oncology market, by therapy
7.3.5.1.2.Germany veterinary oncology market, by animal type
7.3.5.1.3.Germany veterinary oncology market, by cancer
7.3.5.2.France
7.3.5.2.1.France veterinary oncology market, by therapy
7.3.5.2.2.France veterinary oncology market, by animal type
7.3.5.2.3.France veterinary oncology market, by cancer
7.3.5.3.UK
7.3.5.3.1.UK veterinary oncology market, by therapy
7.3.5.3.2.UK veterinary oncology market, by animal type
7.3.5.3.3.UK veterinary oncology market, by cancer
7.3.5.4.Italy
7.3.5.4.1.Italy veterinary oncology market, by therapy
7.3.5.4.2.Italy veterinary oncology market, by animal type
7.3.5.4.3.Italy veterinary oncology market, by cancer
7.3.5.5.Spain
7.3.5.5.1.Spain veterinary oncology market, by therapy
7.3.5.5.2.Spain veterinary oncology market, by animal type
7.3.5.5.3.Spain veterinary oncology market, by cancer
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe veterinary oncology market, by therapy
7.3.5.6.2.Rest of Europe veterinary oncology market, by animal type
7.3.5.6.3.Rest of Europe veterinary oncology market, by cancer
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific veterinary oncology market, by therapy
7.4.3.Asia-Pacific veterinary oncology market, by animal type
7.4.4.Asia-Pacific veterinary oncology market, by cancer
7.4.5.Market size and forecast, by country
7.4.5.1.Japan
7.4.5.1.1.Japan veterinary oncology market, by therapy
7.4.5.1.2.Japan veterinary oncology market, by animal type
7.4.5.1.3.Japan veterinary oncology market, by cancer
7.4.5.2.China
7.4.5.2.1.China veterinary oncology market, by therapy
7.4.5.2.2.China veterinary oncology market, by animal type
7.4.5.2.3.China veterinary oncology market, by cancer
7.4.5.3.Australia
7.4.5.3.1.Australia veterinary oncology market, by therapy
7.4.5.3.2.Australia veterinary oncology market, by animal type
7.4.5.3.3.Australia veterinary oncology market, by cancer
7.4.5.4.India
7.4.5.4.1.India veterinary oncology market, by therapy
7.4.5.4.2.India veterinary oncology market, by animal type
7.4.5.4.3.India veterinary oncology market, by cancer
7.4.5.5.South Korea
7.4.5.5.1.South Korea veterinary oncology market, by therapy
7.4.5.5.2.South Korea veterinary oncology market, by animal type
7.4.5.5.3.South Korea veterinary oncology market, by cancer
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific veterinary oncology market, by therapy
7.4.5.6.2.Rest of Asia-Pacific veterinary oncology market, by animal type
7.4.5.6.3.Rest of Asia-Pacific veterinary oncology market, by cancer
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA veterinary oncology market, by therapy
7.5.3.LAMEA veterinary oncology market, by animal type
7.5.4.LAMEA veterinary oncology market, by cancer
7.5.5.Market size and forecast, by country
7.5.5.1.Brazil
7.5.5.1.1.Brazil veterinary oncology market, by therapy
7.5.5.1.2.Brazil veterinary oncology market, by animal type
7.5.5.1.3.Brazil veterinary oncology market, by cancer
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia veterinary oncology market, by therapy
7.5.5.2.2.Saudi Arabia veterinary oncology market, by animal type
7.5.5.2.3.Saudi Arabia veterinary oncology market, by cancer
7.5.5.3.South Africa
7.5.5.3.1.South Africa veterinary oncology market, by therapy
7.5.5.3.2.South Africa veterinary oncology market, by animal type
7.5.5.3.3.South Africa veterinary oncology market, by cancer
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA veterinary oncology market, by therapy
7.5.5.4.2.Rest of LAMEA veterinary oncology market, by animal type
7.5.5.4.3.Rest of LAMEA veterinary oncology market, by cancer
CHAPTER 8:COMPANY PROFILES
8.1.AB Science
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.Accuray Incorporated
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.Boehringer Ingelheim International GmbH
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments
8.4.Elanco Animal Health Incorporated
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.Karyopharm Therapeutics, Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.Morphogenesis, Inc.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Product portfolio
8.7.PetCure Oncology
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Key strategic moves and developments
8.8.Regeneus Ltd.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.Varian Medical System, Inc.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.Zoetis
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020–2030 ($MILLION)
TABLE 02.SURGERY VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 03.RADIOLOGY VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.CHEMOTHERAPY VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.OTHERS VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 06.GLOBAL VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020–2030 ($MILLION)
TABLE 07.CANINE VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 08.CANINE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030($MILLION)
TABLE 09.FELINE VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 10.FELINE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030($MILLION)
TABLE 11.GLOBAL VETERINARY ONCOLOGY MARKET, BY CANCER, 2020–2030 ($MILLION)
TABLE 12.LYMPHOMA VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 13.MAST CELL CANCER VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 14.MAMMARY AND SQUAMOUS CELL CANCER VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 15.OTHERS VETERINARY ONCOLOGY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 16.VETERINARY ONCOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 20.NORTH AMERICA VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21.U.S. VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 22.U.S. VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 23.U.S. VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 24.CANADA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 25.CANADA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 26.CANADA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 27.MEXICO VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 28.MEXICO VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 29.MEXICO VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 30.EUROPE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 31.EUROPE VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 32.EUROPE VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 33.EUROPE VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34.GERMANY VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 35.GERMANY VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 36.GERMANY VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 37.FRANCE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 38.FRANCE VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 39.FRANCE VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 40.UK VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 41.UK VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 42.UK VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 43.ITALY VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 44.ITALY VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 45.ITALY VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 46.SPAIN VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 47.SPAIN VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 48.SPAIN VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 49.REST OF EUROPE VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 50.REST OF EUROPE VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 51.REST OF EUROPE VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 52.ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 53.ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 54.ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 55.ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56.JAPAN VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 57.JAPAN VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 58.JAPAN VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 59.CHINA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 60.CHINA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 61.CHINA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 62.AUSTRALIA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 63.AUSTRALIA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 64.AUSTRALIA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 65.INDIA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 66.INDIA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 67.INDIA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 68.SOUTH KOREA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 70.SOUTH KOREA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 74.LAMEA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 75.LAMEA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 76.LAMEA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 77.LAMEA VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78.BRAZIL VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 79.BRAZIL VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 80.BRAZIL VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 81.SAUDI ARABIA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 82.SAUDI ARABIA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 83.SAUDI ARABIA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 84.SOUTH AFRICA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 85.SOUTH AFRICA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 86.SOUTH AFRICA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 87.REST OF LAMEA VETERINARY ONCOLOGY MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 88.REST OF LAMEA VETERINARY ONCOLOGY MARKET, BY ANIMAL TYPE, 2020-2030 ($MILLION)
TABLE 89.REST OF LAMEA VETERINARY ONCOLOGY MARKET, BY CANCER, 2020-2030 ($MILLION)
TABLE 90.AB SCIENCE: COMPANY SNAPSHOT
TABLE 91.AB SCIENCE: OPERATING SEGMENT
TABLE 92.AB SCIENCE: PRODUCT PORTFOLIO
TABLE 93.ACCURAY: COMPANY SNAPSHOT
TABLE 94.ACCURAY: OPERATING SEGMENT
TABLE 95.ACCURAY: PRODUCT PORTFOLIO
TABLE 96.ACCURAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 98.BOEHRINGER INGELHEIM: OPERATING SEGMENT
TABLE 99.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 100.BOEHRINGER INGELHEIM: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101.ELANCO: COMPANY SNAPSHOT
TABLE 102.ELANCO: OPERATING SEGMENT
TABLE 103.ELANCO: PRODUCT PORTFOLIO
TABLE 104.ELANCO: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.KARYOPHARM: COMPANY SNAPSHOT
TABLE 106.KARYOPHARM: OPERATING SEGMENT
TABLE 107.KARYOPHARM: PRODUCT PORTFOLIO
TABLE 108.MORPHOGENESIS: COMPANY SNAPSHOT
TABLE 109.MORPHOGENESIS: PRODUCT PORTFOLIO
TABLE 110.PETCURE ONCOLOGY: COMPANY SNAPSHOT
TABLE 111.PETCURE ONCOLOGY: OPERATING SEGMENT
TABLE 112.PETCURE ONCOLOGY: PRODUCT PORTFOLIO
TABLE 113.PETCURE ONCOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114.REGENEUS: COMPANY SNAPSHOT
TABLE 115.REGENEUS: OPERATING SEGMENT
TABLE 116.REGENEUS: PRODUCT PORTFOLIO
TABLE 117.VARIAN: COMPANY SNAPSHOT
TABLE 118.VARIAN: OPERATING SEGMENT
TABLE 119.VARIAN: PRODUCT PORTFOLIO
TABLE 120.ZOETIS: COMPANY SNAPSHOT
TABLE 121.ZOETIS: OPERATING SEGMENT
TABLE 122.ZOETIS: PRODUCT PORTFOLIO
TABLE 123.ZOETIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.VETERINARY ONCOLOGY MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF SURGERY VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF RADIOLOGY VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF CHEMOTHERAPY VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF OTHERS VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF CANINE VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF FELINE VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF LYMPHOMA VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF MAST CELL CANCER VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF MAMMARY AND SQUAMOUS CELL CANCER VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF OTHERS VETERINARY ONCOLOGY MARKET, BY COUNTRY, 2020–2030 (%)
FIGURE 23.AB SCIENCE: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.ACCURAY: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.ACCURAY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 26.ACCURAY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 27.BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 29.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 30.ELANCO: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.ELANCO: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 32.ELANCO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 33.KARYOPHARM: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.REGENEUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.VARIAN: NET SALES, 2017–2029 ($MILLION)
FIGURE 36.VARIAN: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 37.VARIAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.ZOETIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.ZOETIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.ZOETIS: REVENUE SHARE, BY REGION, 2020 (%)